# Study of 68Ga-R10602

> **NCT06745804** · PHASE1 · RECRUITING · sponsor: **Radionetics Oncology** · enrollment: 36 (estimated)

## Conditions studied

- Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
- Metastatic Hormone Receptor Positive Breast Cancer
- Hormone Receptor Positive Breast Adenocarcinoma

## Interventions

- **DRUG:** 68Ga-R10602 injection

## Key facts

- **NCT ID:** NCT06745804
- **Lead sponsor:** Radionetics Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-10
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06745804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06745804, "Study of 68Ga-R10602". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06745804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*